Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia

Article

关键词: LOW-DENSITY-LIPOPROTEIN;    LDL-RECEPTOR GENE;    CHOLESTEROL ABSORPTION INHIBITOR;    CORONARY-HEART-DISEASE;    MUTATIONS;    LOCUS;    DISPOSITION;    MANAGEMENT;    APHERESIS;    SOFTWARE;   

DOI  :  10.1161/01.CIR.0000018744.58460.62

来源: SCIE

【 摘 要 】

Background-Patients with homozygous familial hypercholesterolemia (HoFH) have a high incidence of cardiovascular morbidity and mortality from premature atherosclerosis, and the efficacy of pharmacological therapy has been limited. We evaluated the efficacy, safety, and tolerability of ezetimibe, a novel cholesterol absorption inhibitor, in a multicenter, double-blind, randomized trial of HoFH patients receiving atorvastatin or simvastatin. Methods and Results-Fifty patients with a diagnosis of HoFH on the National Cholesterol Education Program Step I or stricter diet and taking open-label atorvastatin 40 mg/d or simvastatin 40 mg/d (statin-40) with (n=25) or without (n=25) concomitant LDL apheresis were randomized to 1 of 3 double-blind treatments: atorvastatin or simvastatin 80 mg/d (statin-80, n= 17); ezetimibe 10 mg/d plus atorvastatin or simvastatin 40 mg/d (n= 16); or ezetimibe 10 mg/d plus atorvastatin or simvastatin 80 mg/d (n= 17) for 12 weeks. The primary end point was mean percentage change in LDL cholesterol (LDL-C) from statin-40 baseline to the end point for patients receiving statins alone (statin-80) versus patients receiving ezetimibe plus atorvastatin or simvastatin at either dose (ezctimibe plus statin-40/80). Ezetimibe plus statin-40/80 significantly reduced LDL-C levels compared with statin-80 (-20.7% versus -6.7%, P=0.007). In the high-dose statin cohorts, ezetimibe plus statin-80 reduced LDL-C by an additional 20.5% (P=0.0001) versus statin-80. Similar significant reductions in LDL-C concentrations were observed for patients with genotype-confirmed HoFH (n=35). Ezetimibe was safe and well tolerated. Conclusions-Ezetimibe coadministered with atorvastatin or simvastatin in patients with HoFH produced clinically important LDL-C reductions compared with best current therapy. Ezetimibe provides a new, complementary pharmacological approach for this high-risk population.

【 授权许可】

Free